[Results of a randomized double-blind multicenter clinical trial of the efficacy and safety of riamilovir in the treatment of COVID-19].
A U SabitovDmitriy A LioznovK V ZhdanovE P TihonovaE V EsaulenkoO P KovtunP L KuznetsovP V SorokinPublished in: Terapevticheskii arkhiv (2024)
As a result of a multicenter randomized double-blind clinical trial, the effectiveness of the drug riamilovir for therapeutic use in patients with COVID-19 according to the 1250 mg/day scheme (250 mg capsules 5 times per day) for 10 days was established. The drug riamilovir in a daily dose of 1250 mg for 10 days does not differ in safety from placebo.